Compare Amgen, Inc. (AMGN) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Li Auto Inc — how do they compare? Amgen, Inc. trades at $356.35 (market cap $196.12B), while Li Auto Inc trades at $12.23 (market cap $11.97B). The key difference: Amgen, Inc. is far larger — about 16.4× Li Auto Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| AMGN | LI | |
|---|---|---|
Market Cap | $196.12B | $11.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $31.80 |
52-Week Low | $271.18 | $11.74 |
Enterprise Value | $241.41B | $888.72M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Li Auto (LI) trades at $12.10, down 1.6% with a bearish technical signal. Recent earnings show volatility with Q1 2026 missing estimates, while cash flow turned negative in 2025. The company faces intense competition and margin pressure, though analyst consensus remains cautiously optimistic with a $14.80 price target. Vehicle deliveries reached 30,895 in June 2026, indicating steady demand despite market headwinds.
Outlook hinges on execution of L series models and recovery from 2025-2026 trough years. Risks include aggressive discounting, regulatory challenges, and macroeconomic pressures in China's EV market. The stock presents a speculative opportunity if operational improvements materialize, but near-term volatility is expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
